000168285 001__ 168285
000168285 005__ 20240419142809.0
000168285 0247_ $$2doi$$a10.4414/smw.2021.20463
000168285 0247_ $$2pmid$$apmid:33793959
000168285 0247_ $$2ISSN$$a0036-7672
000168285 0247_ $$2ISSN$$a1424-3997
000168285 0247_ $$2ISSN$$a1424-7860
000168285 0247_ $$2altmetric$$aaltmetric:103132329
000168285 037__ $$aDKFZ-2021-00796
000168285 041__ $$aEnglish
000168285 082__ $$a610
000168285 1001_ $$aAndres, Martin$$b0
000168285 245__ $$aTrends of incidence, mortality and survival for chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland between 1997 and 2016: a population-based study.
000168285 260__ $$aBasel$$bEMH Schweizerischer Ärzteverl.$$c2021
000168285 3367_ $$2DRIVER$$aarticle
000168285 3367_ $$2DataCite$$aOutput Types/Journal article
000168285 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1713529624_13215
000168285 3367_ $$2BibTeX$$aARTICLE
000168285 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168285 3367_ $$00$$2EndNote$$aJournal Article
000168285 520__ $$aDuring the last 20 years, treatment for chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL) has advanced, with improved clinical outcomes in randomised controlled trials. Currently, no data have been published from Switzerland to assess effectiveness of recent healthcare advances in CLL/SLL on a population-based level. We aimed to estimate trends in incidence, mortality and survival for patients with CLL/SLL in Switzerland.We retrospectively studied registry data from the National Agency for Cancer Registration (NACR) database in Switzerland from 1997 to 2016. We investigated incidence, mortality and survival in consecutive 5-year periods. Age-specific rates were calculated for three age groups (<65 years, 65&ndash;74 years and &ge;75 years).We obtained 6301 cases with CLL/SLL. Median age at diagnosis was 72 years. From 7.0 per 100,000 person-years in 1997&ndash;2002, age-adjusted incidence rates peaked at 7.8 per 100,000 person-years in the second time period, 2002&ndash;2006, and declined afterwards to 6.4 per 100,000 person-years in 2012&ndash;2016. Mortality declined from 2.4 per 100,000 person-years in 1997&ndash;2002 to 2.0 per 100,000 in 2012&ndash;2016. Five- and 10-year age-standardised relative survival increased from 77.9% and 55.6%, respectively, in 1997&ndash;2001 to 83.6% (p = 0.009) and 64.2% (p = 0.005), respectively, in 2012&ndash;2016. Improvement in age-specific relative survival was only significant in the middle age group (65&ndash;74 years). Incidence and mortality were significantly higher in males. Females had better relative survival.We found no clear down- or upward trend in age-adjusted incidence rates. Age-standardised survival improved over time, mainly in the two younger age-groups, but this improvement was statistically significant in those aged 65&ndash;74 years only. Males have higher incidence rates, higher mortality and shorter survival than females. Reporting delay and underreporting are major limitations in the interpretation of registry data from patients diagnosed with CLL/SLL.
000168285 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000168285 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168285 7001_ $$aFeller, Anita$$b1
000168285 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b2$$eLast author$$udkfz
000168285 7001_ $$aGroup, The Nicer Working$$b3
000168285 773__ $$0PERI:(DE-600)2031164-3$$a10.4414/smw.2021.20463$$gVol. 151$$pw20463$$tSwiss medical weekly$$v151$$x0036-7672$$y2021
000168285 909CO $$ooai:inrepo02.dkfz.de:168285$$pVDB
000168285 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000168285 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000168285 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000168285 9141_ $$y2021
000168285 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-27
000168285 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSWISS MED WKLY : 2019$$d2021-01-27
000168285 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-27
000168285 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000168285 980__ $$ajournal
000168285 980__ $$aVDB
000168285 980__ $$aI:(DE-He78)C071-20160331
000168285 980__ $$aUNRESTRICTED